A citation-based method for searching scientific literature

Luke McLean, Jose Luis Leal, Benjamin J Solomon, Thomas John. Transl Lung Cancer Res 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
587
100

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.
Marjorie Aubanel, Aurélie Swalduz, Virginie Avrillon, Louis Doublet, Bénédicte Mastroianni, Eve-Marie Neidhardt-Bérard, Maurice Pérol. Clin Lung Cancer 2020
2
100



EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, Geoffrey Y Ku, Yaelle Tuvy, Helen Won, Christopher J Fong, Nancy Bouvier, Gouri J Nanjangud, Joanne Soong,[...]. Cancer Discov 2019
61
100

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
Dan Lu, Tong Lu, Mark Stroh, Richard A Graham, Priya Agarwal, Luna Musib, Chi-Chung Li, Bert L Lum, Amita Joshi. Cancer Chemother Pharmacol 2016
33
100

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.
Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G S Mortimer, Justin I Odegaard, Elizabeth A Harrington, Juyoung Lee, Taehyang Lee,[...]. Cancer Discov 2019
55
100

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
59
100

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Romain Varnier, Olivia Le Saux, Sylvie Chabaud, Gwenaëlle Garin, Emilie Sohier, Qing Wang, Sandrine Paindavoine, David Pérol, Christian Baudet, Valéry Attignon,[...]. Eur J Cancer 2019
4
100

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
181
100

The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
514
100

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
100

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
519
100

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.
Steven B Maron, Lindsay Alpert, Heewon A Kwak, Samantha Lomnicki, Leah Chase, David Xu, Emily O'Day, Rebecca J Nagy, Richard B Lanman, Fabiola Cecchi,[...]. Cancer Discov 2018
66
100

Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
Yang Liu, Nilay S Sethi, Toshinori Hinoue, Barbara G Schneider, Andrew D Cherniack, Francisco Sanchez-Vega, Jose A Seoane, Farshad Farshidfar, Reanne Bowlby, Mirazul Islam,[...]. Cancer Cell 2018
177
100

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
303
100

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Yelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K Chatila, Jaclyn F Hechtman, Geoffrey Y Ku, Jamie C Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier,[...]. Cancer Discov 2018
143
100

State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric-Bernstam. J Clin Oncol 2020
56
100

Global burden of oesophageal and gastric cancer by histology and subsite in 2018.
Melina Arnold, Jacques Ferlay, Mark I van Berge Henegouwen, Isabelle Soerjomataram. Gut 2020
40
100

HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh, Yung-Jue Bang. Nat Rev Clin Oncol 2020
154
100

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, Justin F Gainor, Inga T Lennes, Viola W Zhu, Nicolas Marcoux, Mandeep K Banwait, Subba R Digumarthy, Wenjia Su,[...]. Cancer Discov 2018
176
100

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Alison M Schram, Matthew T Chang, Philip Jonsson, Alexander Drilon. Nat Rev Clin Oncol 2017
133
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.